Myungmoon teams up with Protherics over ReGel

Published: 2007-10-02 06:57:00

Updated: 2007-10-02 06:57:00

Myungmoon Pharm said on September 24 that it signed a licensing agreement with London-based Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, to develop anti-inflammatory products using Protherics' novel proprietary local, sustained release drug deli...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK